Kaleido Biosciences to Participate in the JMP Securities Life Sciences Conference

LEXINGTON, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that CEO Dan Menichella will deliver a corporate presentation at the JMP Securities Life Sciences Conference at 4PM ET on Thursday, June 17.

The webcast of the presentation will be made available in the Investors & Media section of Kaleido’s website at https://investors.kaleido.com/events-presentations. An archived replay will be available for 90 days following the event.

About Kaleido BiosciencesKaleido Biosciences is a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health. The Company has built a proprietary product platform to enable the rapid and cost-efficient discovery and development of novel Microbiome Metabolic Therapies (MMT™). MMTs are designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the gut’s existing microbes. Kaleido is advancing a broad pipeline of MMT candidates with the potential to address a variety of diseases and conditions with significant unmet patient needs. To learn more, visit https://kaleido.com/.

Contacts:

Kaleido BiosciencesWilliam Duke, Jr.Chief Financial Officer617-890-5772[email protected]

InvestorsMike BiegaSolebury Trout617-221-9660[email protected]

MediaAmy BonannoSolebury Trout914-450-0349[email protected]

You May Also Be Interested In

• At UN General Assembly, Global Autism Advocacy Coalition launches new initiatives to accelerate autism action worldwide
• XRP Price Prediction: Binance XRP Inflows Jump 663% but Almost None Gets Sold as AlphaPepe Listing Buzz Builds
• Best Crypto to Buy Under $1: Remittix Offers a Different Entry From XRP Ahead of November